Navigation Links
Idenix Pharmaceuticals Reports Second Quarter and Six Month 2009 Financial Results
Date:7/20/2009

Loss from operations (16,306) (19,647) (29,623) (41,448) Other income(expense), net (249) 485 (297) 1,425 ----- --- ----- ----- Loss before income taxes (16,555) (19,162) (29,920) (40,023) Income tax benefit 241 256 679 657 --- --- --- --- Net loss $(16,314) $(18,906) $(29,241) $(39,366) ========= ========= ========= ========= Basic and diluted net loss per share: ($0.28) ($0.34) ($0.50) ($0.70) ======= ======= ======= ======= Shares used in calculation of basic and diluted net loss per share: 59,077 56,359 58,014 56,316 ====== ====== ====== ====== (1) Share-based compensation expenses included in operating expenses amounted to approximately: Research and development $408 $467 $847 $1,127 General and administrative 783 876 1,599 1,755 IDENIX PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (IN THOUSANDS) (UNAUDITED) June 30, December 31, 2009 2008 ASSETS ---- ---- Cash and cash equivalents $50,128 $41,509 Marketable securities -- 1,424 Receivables from related party 843 894 Other current assets 3,729 6,214
'/>"/>
SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Idenix to Host Conference Call Discussing Second Quarter 2009 Financial Results
2. Idenix Pharmaceuticals to Present at The Deutsche Bank 2009 Health Care Conference
3. Idenix Pharmaceuticals Reports First Quarter Financial Results
4. Idenix Pharmaceuticals Reports Data From Three Hepatitis C Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver
5. Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference
6. Idenix Announces Data Presentations from Three HCV Discovery and Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL)
7. Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results
8. Idenix to Host Conference Call Discussing Fourth Quarter 2008 Financial Results
9. Idenix Pharmaceuticals to Present at the JP Morgan 27th Annual Healthcare Conference
10. Idenix Pharmaceuticals to Present at Deutsche Banks 2008 Biotech Boston Confab
11. Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Climate projections underestimate CO2 impact 2University of Washington professor garners Avanti Young Investigator Award 2New engineering institute to modify, develop technology for the global poor 2New engineering institute to modify, develop technology for the global poor 3Hard To Treat Diseases 28HTDS 29 Delivers Varicella Vaccine To Guatemala 58001 1Hard To Treat Diseases 28HTDS 29 Delivers Varicella Vaccine To Guatemala 58001 2Hard To Treat Diseases 28HTDS 29 Delivers Varicella Vaccine To Guatemala 58001 3EHRtv com Introduces Allscripts Channel Featuring Presentations Client Interviews and Keynote from National User Conference 58000 1EHRtv com Introduces Allscripts Channel Featuring Presentations Client Interviews and Keynote from National User Conference 58000 2Reportlinker Adds Nosocomial Infections 3A Market Impact on Diagnostics and Therapeutics 3A 28MRSA HAP C diff and other Hospital Acquired Infectio 57998 1Reportlinker Adds Nosocomial Infections 3A Market Impact on Diagnostics and Therapeutics 3A 28MRSA HAP C diff and other Hospital Acquired Infectio 57998 2Reportlinker Adds Nosocomial Infections 3A Market Impact on Diagnostics and Therapeutics 3A 28MRSA HAP C diff and other Hospital Acquired Infectio 57998 3Reportlinker Adds Nosocomial Infections 3A Market Impact on Diagnostics and Therapeutics 3A 28MRSA HAP C diff and other Hospital Acquired Infectio 57998 4Reportlinker Adds Nosocomial Infections 3A Market Impact on Diagnostics and Therapeutics 3A 28MRSA HAP C diff and other Hospital Acquired Infectio 57998 5Reportlinker Adds Nosocomial Infections 3A Market Impact on Diagnostics and Therapeutics 3A 28MRSA HAP C diff and other Hospital Acquired Infectio 57998 6